Dr. Mou, CEO of Correctseq, Participates in Cell and Gene Therapy Non-Clinical Evaluation Salon and Makes a Speech

2022-10-15 15:23:55 e-Safe 73

图片关键词

Oct 15, 2022, the Fourth Cell and Gene Therapy Non-Clinical Evaluation Salon organized by Drug Toxicology Committee of Chinese Pharmacological Society, Drug Toxicology and Safety Evaluation Committee of Chinese Society of Toxicology, and Tsinghua University, was successfully held online. The salon’s theme was Oncolytic Viruses, Gene Editing and R&D Cases. Dr. Mou, CEO of Correctseq, participated in the salon and made a speech titled How to Create Innovative Gene Editing System and Make Its Clinical Application Safety. The Chairman of Drug Toxicology and Safety Evaluation Committee of Chinese Society of Toxicology, Dr. Mingyang Liao participated in the salon and make an opening speech. The Chairman of the salon, Deputy Editor-in-Chief of Tsinghua University Press, Yu Sun, and the Chairman of the salon, Deputy Chairman and Secretary-General of Drug Toxicology and Safety Evaluation Committee of Chinese Society of Toxicology, Vice President of Suzhou Pharmaceutical Research Institute, Quanjun Wang hosted the salon. 

The salon has two topics: "Oncolytic Virus Drug R&D Strategies and Cases" and "Gene Editing Product R&D Strategies and Cases". In the topic of "Gene Editing Product R&D Strategies and Cases", Dr. Mou, CEO of Correctseq, introduced the advantages, clinical application and safety controlling of innovative Base Editing system, represented by tBE (transformer Base Editor) which was created by scientific co-founders of Correctseq. Meanwhile, Dr. Mou discussed how to evaluate possibilities of off-target mutations of gene editing with audiences and experts.

图片关键词

Figure: Dr. Mou, CEO of Correctseq, made a speech titled How to Create Innovative Gene Editing System and Make Its Clinical Application Safety

As a new gene editing biomedical technology company, Correctseq have developed multiple base editing systems and the base editors offer significant advantages in controlling off-target effects and improving in vivo editing efficiency. Base Editing is developed based on CRISPR, which can keep DNA double strand integrity while correcting point mutations precisely. It had solved the source problems such as large chromosome deletion and chromosomal translocation caused by DNA double strand breaks caused by previous generations of gene editing technology and has higher editing efficiency, safety and druggability. 

Since the First Cell and Gene Therapy Non-Clinical Evaluation Salon was held online on March 26, 2022, the total number of plays has exceeded 35,000 times. The audience all expressed that this series of salons can solve the difficulties in actual research and development, clarify the ideas of experiment and product development, and better improve the evaluation and research technology of cell and gene therapy. It is hoped that this kind of salons can become a high-level forum, help institutions scientific research and enterprise produce, and promote the development of cell and gene therapy industry.

Cell and gene therapy is one of the hottest research areas at home and abroad in the medical industry and is expected to become the most important therapeutic approach to cure cancer and other difficult diseases. However, there is no complete and systematic guide for its non-clinical evaluation. This theme series of salons will continue to be held, to build a platform for online and offline communication, domestic and foreign interaction, to promote the healthy development of the industry.

(The article is reprinted from e-Safe WeChat)


CorrectSequence Therapeutics Co., Ltd. © (2021-2022)
沪ICP备2020032248号
Powered by MetInfo 7.7 ©2008-2024  mituo.cn
HOME
ABOUT
NEWS
CONTACT